{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:06:36Z","timestamp":1791230796134,"version":"4.1.0"},"reference-count":61,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to evaluate the risk of colorectal adenocarcinoma (CRA) associated with long-term use of proton pump inhibitors (PPIs) in a large nationwide cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>This research was conducted at the national level, encompassing the entire population of Sweden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>This study utilised Swedish national registries to identify all adults who had \u2265180 days of cumulative PPI use between July 2005 and December 2012, excluding participants who were followed up for less than 1 year. A total of 754\u2009118 maintenance PPI users were included, with a maximum follow-up of 7.5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>\n                      Maintenance PPI use (cumulative\u2265180 days), with a comparator of maintenance histamine-2 receptor antagonist (H\n                      <jats:sub>2<\/jats:sub>\n                      RA) use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>\n                      The primary outcome measure was the risk of CRA, presented as standardised incidence ratios (SIRs) with 95% confidence intervals (CIs). Subgroup analyses were performed to explore the impact of indications, tumour locations, tumour stages and the duration of follow-up. A multivariable Poisson regression model was fitted to estimate the incidence rate ratios (IRRs) and 95% CIs of PPI versus H\n                      <jats:sub>2<\/jats:sub>\n                      RA use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Maintenance PPI users exhibited a slightly elevated risk of CRA compared to the general population (SIR 1.10, 95% CI=1.06 to 1.13) for both men and women. Individuals aged 18\u201339 (SIR 2.79, 95% CI=1.62 to 4.47) and 40\u201349 (SIR 2.02, 95% CI=1.65 to 2.45) had significantly higher risks than the general population. Right-sided CRA showed a higher risk compared to the general population (SIR 1.26, 95% CI=1.20 to 1.32). There was no significant difference in the risk of CRA between maintenance PPI users and maintenance H\n                      <jats:sub>2<\/jats:sub>\n                      RA users (IRR 1.05, 95% CI=0.87 to 1.27,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Maintenance PPI use may be associated with an increased risk of CRA, but a prolonged observation time is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-079591","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:41:46Z","timestamp":1719967306000},"page":"e079591","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Maintenance proton pump inhibitor use and risk of colorectal cancer: a Swedish retrospective cohort study"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1663-189X","authenticated-orcid":false,"given":"Qing","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchen","family":"Wang","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Engstrand","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Sadr-Azodi","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Surgery, Capio Saint G\u00f6ran Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Fall","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Biostatistics School of Medical Sciences, \u00d6rebro University, \u00d6rebro, Sweden"},{"name":"Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0137-447X","authenticated-orcid":false,"given":"Nele","family":"Brusselaers","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Head and Skin, Ghent University, Ghent, Belgium"},{"name":"Global Health Institute, Antwerp University, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"2025121300143296000_14.7.e079591.1","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-008-0098-4"},{"key":"2025121300143296000_14.7.e079591.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.06.022"},{"key":"2025121300143296000_14.7.e079591.3","doi-asserted-by":"crossref","unstructured":"H\u00e1lfd\u00e1narson \u00d3\u00d6 , Potteg\u00e5rd A , Bj\u00f6rnsson ES , et al . Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol 2018;11. doi:10.1177\/1756284818777943","DOI":"10.1177\/1756284818777943"},{"key":"2025121300143296000_14.7.e079591.4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00228-019-02810-1","article-title":"Use of proton pump inhibitors in adults in France: a nationwide drug utilization study","volume":"76","author":"Lassalle","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2025121300143296000_14.7.e079591.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.031"},{"key":"2025121300143296000_14.7.e079591.6","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.444"},{"key":"2025121300143296000_14.7.e079591.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.12.247"},{"key":"2025121300143296000_14.7.e079591.8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jamainternmed.2020.2441","article-title":"Deprescribing proton pump inhibitors","volume":"180","author":"Kurlander","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2025121300143296000_14.7.e079591.9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canep.2018.02.004","article-title":"Maintenance proton pump inhibition therapy and risk of oesophageal cancer","volume":"53","author":"Brusselaers","year":"2018","journal-title":"Cancer Epidemiology"},{"key":"2025121300143296000_14.7.e079591.10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/apt.13450","article-title":"Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with Pantoprazole and other proton pump inhibitors","volume":"43","author":"Schneider","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121300143296000_14.7.e079591.11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00535-019-01652-z","article-title":"Long-term proton pump inhibitor usage and the association with Pancreatic cancer in Sweden","volume":"55","author":"Brusselaers","year":"2020","journal-title":"J Gastroenterol"},{"key":"2025121300143296000_14.7.e079591.12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310376"},{"key":"2025121300143296000_14.7.e079591.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14177-z"},{"key":"2025121300143296000_14.7.e079591.14","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1038\/s41467-022-33050-0","article-title":"An online atlas of human plasma metabolite signatures of gut microbiome composition","volume":"13","author":"Dekkers","year":"2022","journal-title":"Nat Commun"},{"key":"2025121300143296000_14.7.e079591.15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i22.2706"},{"key":"2025121300143296000_14.7.e079591.16","doi-asserted-by":"crossref","unstructured":"Chen CC , Liou JM , Lee YC , et al . The interplay between helicobacter pylori and gastrointestinal microbiota . Gut Microbes 2021;13. doi:10.1080\/19490976.2021.1909459","DOI":"10.1080\/19490976.2021.1909459"},{"key":"2025121300143296000_14.7.e079591.17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.micpath.2017.09.041","article-title":"Gut biofilm forming bacteria in inflammatory bowel disease","volume":"112","author":"Srivastava","year":"2017","journal-title":"Microbial Pathogenesis"},{"key":"2025121300143296000_14.7.e079591.18","doi-asserted-by":"crossref","unstructured":"Lei W-Y , Wang J-H , Yi C-H , et al . Association between use of proton pump inhibitors and colorectal cancer: a nationwide population-based study. Clin Res Hepatol Gastroenterol 2021;45. doi:10.1016\/j.clinre.2020.02.017","DOI":"10.1016\/j.clinre.2020.02.017"},{"key":"2025121300143296000_14.7.e079591.19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ajco.12054","article-title":"Use of proton pump inhibitors correlates with increased risk of colorectal cancer in Taiwan","volume":"9","author":"Lai","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025121300143296000_14.7.e079591.20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.06.014"},{"key":"2025121300143296000_14.7.e079591.21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/pds.1749","article-title":"Colorectal cancer risk in relation to use of acid suppressive medications","volume":"18","author":"Chubak","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121300143296000_14.7.e079591.22","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1572-0241.2007.01665.x","article-title":"Proton pump inhibitors and the risk of colorectal cancer","volume":"103","author":"van Soest","year":"2008","journal-title":"Am J Gastroenterology"},{"key":"2025121300143296000_14.7.e079591.23","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000591"},{"key":"2025121300143296000_14.7.e079591.24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ygh2.409","article-title":"Proton pump inhibitors are not associated with an increased risk of colorectal cancer","volume":"2","author":"Kuiper","year":"2020","journal-title":"GastroHep"},{"key":"2025121300143296000_14.7.e079591.25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325096"},{"key":"2025121300143296000_14.7.e079591.26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ajco.12054","article-title":"Use of proton pump inhibitors correlates with increased risk of colorectal cancer in T Aiwan","volume":"9","author":"Lai","year":"2013","journal-title":"Asia-Pac J Clncl Oncology"},{"key":"2025121300143296000_14.7.e079591.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189114","article-title":"Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: a Korean nationwide prospective cohort study","volume":"12","author":"Hwang","year":"2017","journal-title":"PLoS One"},{"key":"2025121300143296000_14.7.e079591.28","doi-asserted-by":"crossref","unstructured":"Thrumurthy SG , Thrumurthy SSD , Gilbert CE , et al . n.d. Colorectal adenocarcinoma: risks, prevention and diagnosis. BMJ:i3590. doi:10.1136\/bmj.i3590","DOI":"10.1136\/bmj.i3590"},{"key":"2025121300143296000_14.7.e079591.29","doi-asserted-by":"publisher","DOI":"10.14740\/gr1062w"},{"key":"2025121300143296000_14.7.e079591.30","doi-asserted-by":"publisher","DOI":"10.5009\/gnl15502"},{"key":"2025121300143296000_14.7.e079591.31","unstructured":"Socialstyrelsen . The National patient register- socialstyrelsen. 2019. Available: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/register-information\/the-national-patient-register\/"},{"key":"2025121300143296000_14.7.e079591.32","unstructured":"Swedish cancer Registry quality. Available: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/register-information\/swedish-cancer-register\/"},{"key":"2025121300143296000_14.7.e079591.33","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-016-0117-y"},{"key":"2025121300143296000_14.7.e079591.34","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0316-1"},{"key":"2025121300143296000_14.7.e079591.35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bcpt.12613","article-title":"The first decade with the Swedish prescribed drug register \u2013 A systematic review of the output in the scientific literature","volume":"119","author":"Wallerstedt","year":"2016","journal-title":"Basic Clin Pharma Tox"},{"key":"2025121300143296000_14.7.e079591.36","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)61602-x"},{"key":"2025121300143296000_14.7.e079591.37","unstructured":"FASS general - home. 2021. Available: https:\/\/www.fass.se\/LIF\/startpage"},{"key":"2025121300143296000_14.7.e079591.38","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802247664"},{"key":"2025121300143296000_14.7.e079591.39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/DCR.0000000000000926","article-title":"The American society of colon and rectal Surgeons clinical practice guidelines for the treatment of colon cancer","volume":"60","author":"Vogel","year":"2017","journal-title":"Dis Colon Rectum"},{"key":"2025121300143296000_14.7.e079591.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021869","article-title":"Maintenance use of non-Steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden","volume":"8","author":"Brusselaers","year":"2018","journal-title":"BMJ Open"},{"key":"2025121300143296000_14.7.e079591.41","doi-asserted-by":"crossref","unstructured":"Machin D , Breslow NE , Day NE . Statistical methods in cancer research. In: The Design and Analysis of Cohort Studies. Biometrics [Internet]. 1990. Available: https:\/\/www.jstor.org\/stable\/2532481?origin=crossref","DOI":"10.2307\/2532481"},{"key":"2025121300143296000_14.7.e079591.42","unstructured":"Statistics database - national board of health and welfare. 2024. Available: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/statistik\/statistikdatabasen\/"},{"key":"2025121300143296000_14.7.e079591.43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-1-59745-416-2_9","article-title":"Introduction to the use of regression models in epidemiology","volume":"471","author":"Bender","year":"2009","journal-title":"Methods Mol Biol"},{"key":"2025121300143296000_14.7.e079591.44","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S109285"},{"key":"2025121300143296000_14.7.e079591.45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.8.914"},{"key":"2025121300143296000_14.7.e079591.46","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312574"},{"key":"2025121300143296000_14.7.e079591.47","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-017-0577-6","article-title":"The gastric and intestinal Microbiome: role of proton pump inhibitors","volume":"19","author":"Minalyan","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"2025121300143296000_14.7.e079591.48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/apt.15604","article-title":"Systematic review: the effects of proton pump inhibitors on the Microbiome of the digestive tract-evidence from next-generation sequencing studies","volume":"51","author":"Macke","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121300143296000_14.7.e079591.49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cgh.2008.09.006","article-title":"Gastrin, Helicobacter Pylori, and colorectal adenomas","volume":"7","author":"Robertson","year":"2009","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"2025121300143296000_14.7.e079591.50","unstructured":"Effects of three H2-receptor antagonists (cimetidine, Famotidine, ranitidine) on serum gastrin Level- PubMed. 2024. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/12503773\/"},{"key":"2025121300143296000_14.7.e079591.51","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3748\/wjg.v4.i6.461","article-title":"Gastrin as an autocrine growth factor in colorectal carcinoma: implications for therapy","volume":"4","author":"Baldwin","year":"1998","journal-title":"WJG"},{"key":"2025121300143296000_14.7.e079591.52","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41416-020-0939-y","article-title":"Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies","volume":"123","author":"Babic","year":"2020","journal-title":"Br J Cancer"},{"key":"2025121300143296000_14.7.e079591.53","unstructured":"Population statistics. 2023. Available: https:\/\/www.scb.se\/en\/finding-statistics\/statistics-by-subject-area\/population\/population-composition\/population-statistics\/"},{"key":"2025121300143296000_14.7.e079591.54","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017739","article-title":"Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden","volume":"7","author":"Brusselaers","year":"2017","journal-title":"BMJ Open"},{"key":"2025121300143296000_14.7.e079591.55","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00228-021-03186-x","article-title":"Successful deprescribing of proton pump inhibitors with a patient-centered process: the DESPIBP project","volume":"77","author":"Calvo","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2025121300143296000_14.7.e079591.56","doi-asserted-by":"crossref","unstructured":"Muheim L , Signorell A , Markun S , et al . Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis. Therap Adv Gastroenterol 2021;14. doi:10.1177\/1756284821998928","DOI":"10.1177\/1756284821998928"},{"key":"2025121300143296000_14.7.e079591.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2017.10.007"},{"key":"2025121300143296000_14.7.e079591.58","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317592"},{"key":"2025121300143296000_14.7.e079591.59","doi-asserted-by":"crossref","unstructured":"Potter JD . n.d. Rising rates of colorectal cancer in younger adults. BMJ. doi:10.1136\/bmj.l4280","DOI":"10.1136\/bmj.l4280"},{"key":"2025121300143296000_14.7.e079591.60","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-0015-y"},{"key":"2025121300143296000_14.7.e079591.61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5114\/aoms.2016.58596","article-title":"Right-and left-sided colon cancer-clinical and pathological differences of the disease entity in one organ","volume":"13","author":"Mik","year":"2017","journal-title":"Arch Med Sci"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-079591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:14:43Z","timestamp":1765613683000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-079591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,2]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/bmjopen-2023-079591"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-079591","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}